Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Neff

Showing results (201-210 of 213) with videos related to

Pageof 22
Sort By:
Plos Genetics|October 3, 2012
Variation in genes related to cochlear biology is strongly associated with adult-onset deafness in border colliesJennifer S Yokoyama, Ernest T Lam, Alison L Ruhe, et al.
The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.
Nature Medicine|June 7, 2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trialLee M Kaplan, Elena Startseva, Carel W le Roux, et al.
Plos One|September 24, 2010
An ADAMTSL2 founder mutation causes Musladin-Lueke Syndrome, a heritable disorder of beagle dogs, featuring stiff skin and joint contracturesHannah L Bader, Alison L Ruhe, Lauren W Wang, et al.
Lancet (London, England)|August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialMazen Noureddin, Juan P Frias, Guy W Neff, et al.
Journal of Hepatology|June 10, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisEric J Lawitz, Mandy Fraessdorf, Guy W Neff, et al.
The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
Science (New York, N.Y.)|August 29, 2009
Coat variation in the domestic dog is governed by variants in three genesEdouard Cadieu, Mark W Neff, Pascale Quignon, et al.
Plos Genetics|September 7, 2018
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysisWilliam P D Hendricks, Victoria Zismann, Karthigayini Sivaprakasam, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Pageof 22

Showing results (201-210 of 213) with videos related to

Sort By:
Pageof 22
Plos Genetics|October 3, 2012
Variation in genes related to cochlear biology is strongly associated with adult-onset deafness in border colliesJennifer S Yokoyama, Ernest T Lam, Alison L Ruhe, et al.
The New England Journal of Medicine|June 7, 2024
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisArun J Sanyal, Pierre Bedossa, Mandy Fraessdorf, et al.
Nature Medicine|June 7, 2026
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trialLee M Kaplan, Elena Startseva, Carel W le Roux, et al.
Plos One|September 24, 2010
An ADAMTSL2 founder mutation causes Musladin-Lueke Syndrome, a heritable disorder of beagle dogs, featuring stiff skin and joint contracturesHannah L Bader, Alison L Ruhe, Lauren W Wang, et al.
Lancet (London, England)|August 16, 2025
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trialMazen Noureddin, Juan P Frias, Guy W Neff, et al.
Journal of Hepatology|June 10, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisEric J Lawitz, Mandy Fraessdorf, Guy W Neff, et al.
The New England Journal of Medicine|May 9, 2025
Efruxifermin in Compensated Liver Cirrhosis Caused by MASHMazen Noureddin, Mary E Rinella, Naga P Chalasani, et al.
Science (New York, N.Y.)|August 29, 2009
Coat variation in the domestic dog is governed by variants in three genesEdouard Cadieu, Mark W Neff, Pascale Quignon, et al.
Plos Genetics|September 7, 2018
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysisWilliam P D Hendricks, Victoria Zismann, Karthigayini Sivaprakasam, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Pageof 22